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Summary
PRINCIPLES: Therapeutic target serum concentrations of
first-line antituberculosis drugs have not been well defined
in clinical studies in tuberculosis (TB) patients.
METHODS: We retrospectively investigated the estimated
maximum serum concentrations (eCmax) of antituberculosis
drugs and clinical outcome of TB patients with therapeutic
drug monitoring performed between 2010–2012 at our in-
stitution, and follow-up until March 2014. The eCmax was
defined as the highest serum concentration during a
sampling period (2, 4 and 6 hours after drug ingestion).
We compared the results with published eCmax values, and
categorised them as either “within reference range”, “low
eCmax”, or “very low eCmax”.Low/very low eCmax-levels
were defined as follows: isoniazid 2–3/<2 mg/l, rifampicin
4–8/<4 mg/l, rifabutin 0.2–0.3/<0.2 mg/l, ethambutol 1–2/
<0.1 mg/l and pyrazinamide <20 mg/l.
RESULTS: Concentrations of antituberculosis drugs in 175
serum samples of 17 patients with TB were analysed. In
12 (71%) patients, multiple therapeutic drug monitoring
samples were collected over time, in 5 (29%) patients only
one sample was available for therapeutic drug monitoring.
Overall, 94% of all patients had at least one low antituber-
culosis drug concentration. Overall, 64% of all eCmax levels
were classified as “low” or “very low”. The eCmax was be-
low the relelvant reference range in 80% of isoniazid, 95%
of rifampicin, 30% of pyrazinamide, and 30% of ethambut-
ol measurements. All but one patient were cured of tuber-
culosis.
CONCLUSIONS: Although many antituberculosis drug
serum concentrations were below the widely used refer-
ence ranges, 16 of 17 patients were cured of tuberculosis.
These results challenge the use of the published reference
ranges for therapeutic drug monitoring.
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Introduction
“The global plan to ‘STOP TB’ 2006–2015” by the World
Health Organization (WHO) aims to eliminate tuberculosis
(TB) by 2050 [1]. In 2013, 9 million new tuberculosis cases
were reported, of which 1.5 million people died from TB.
TB is a major cause of death worldwide, and the leading
cause of death in individuals infected with the human im-
munodeficiency virus (HIV) in resource-limited areas [2].
Well-conducted 6-month TB treatment is effective: cure
rates of >95% can be achieved in pulmonary TB under dir-
ectly observed therapy [2–4]. In contrast, in resource-lim-
ited countries with a high TB incidence, the success rate
can be as low as 40–60% [5].
Several factors complicate TB treatment. Case series [6, 7]
and noncontrolled clinical studies [8–12] indicate that HIV
infection may increase the risk of poor absorption of an-
tituberculosis drugs, especially rifampicin. There are sig-
nificant drug-drug interactions with antiretroviral therapy.
Opportunistic infections and other comorbidities are of im-
portance as well. Chronic diarrhoea, for instance, might
influence efficacy of antituberculosis treatment. Hence,
therapeutic drug monitoring could be an important tool to
guide TB treatment. While the reference ranges reported
by Peloquin are often used [13], no clear evidence links
low antituberculosis drug serum concentrations to treat-
ment failure. Few clinical studies have compared antituber-
culosis drug concentrations and clinical outcome [14, 15].
Furthermore, the results of studies are difficult to interpret
as they differ in treatment duration, drug formulation, dos-
ing regimen, time of sample collection and population
[15–19].
The University Hospital of Zurich, Switzerland, is a large
referral hospital caring for complex TB cases, on average
20 TB patients a year, and offering therapeutic drug mon-
itoring of antituberculosis drugs since 2010. Our aim was
to study retrospectively the characteristics and outcomes
of patients with TB in whom therapeutic drug monitoring
of first-line antituberculosis drugs was performed, and to
determine whether maximum serum concentrations below
published reference ranges influenced TB treatment out-
come.
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Material and methods
Study population and procedures
All adult inpatients and outpatients treated for TB were eli-
gible if at least one antituberculosis drug serum concen-
tration measurement was performed between August 2010
and April 2012. Patients were included if TB treatment was
initiated on the basis of proven diagnosis or high suspicion
of TB. Patients with a mycobacterial infection other than
TB were excluded. The follow-up period lasted until the
end of March 2014. In cases where treatment was not ter-
minated at our institution, patients or their family physi-
cians were contacted by phone and were asked about treat-
ment outcome.
TB was proven if a sputum smear for acid-fast bacilli
and culture or polymerase chain-reaction (PCR) testing of
any specimen was positive for Mycobacterium tuberculos-
is complex. TB was highly suspected if culture, PCR or
sputum smear were negative but the clinical pattern was
highly suggestive of TB [5], particularly in terms of the
patient’s origin, possible exposure to TB, immunosuppres-
sion, fever, night sweats, weight loss of >10% within 6
months and radiological findings. Patients were treated for
pulmonary, extrapulmonary or disseminated TB according
to national and international recommendations [2, 3]. For
pulmonary TB, patients received 2 months of isoniazid, ri-
fampicin or rifabutin, pyrazinamide and ethambutol, fol-
lowed by 4 months of isoniazid and rifampicin or rifabutin,
with a longer duration of up to 12 months for TB men-
ingitis or bone involvement. Changes of antituberculosis
drug dosage were at the treating physicians’ discretion.
Prolonged length of treatment was due to disease persisten-
ce.
Proposed sampling timepoints for therapeutic drug monit-
oring were 2, 4, and 6 hours after drug ingestion, without
a firm protocol. Physicians were encouraged to adhere to
these sampling times. Light-protected blood samples were
transferred to the internal laboratory within 60 minutes of
blood draw, and the serum was separated by centrifugation
and frozen immediately until analysis (–20 °C).
Serum concentrations of the drugs were analysed by val-
idated high-performance liquid chromatography tandem
mass spectrometry methods. Intra- and inter-day impreci-
sion was <10%, and intra- and inter-day inaccuracy was
90–110%. Matrix effects could be excluded during relevant
times.
Clinical information was compiled from hospital medical
records. Antituberculosis drug- and therapeutic drug
monitoring-specific data included dosage at treatment on-
set, dose adjustments, antituberculosis drug resistance, spu-
tum check-up data, ingestion time (fasting or not), adverse
drug-reactions, treatment duration, treatment outcome, and
reasons for therapeutic drug monitoring.
The study protocol was approved by the local ethics com-
mittee.
Data analysis and treatment outcome
The highest measured value within a sampling period, in-
dependent of blood sampling time and frequency, was
defined as the estimated maximum peak serum concen-
tration (eCmax). Correlation of antituberculosis drug dose
(mg) versus eCmax was investigated by use of linear re-
gression analysis (Sigma Plot version 12.0). For outcome
comparisons, eCmax was classified as either “within refer-
ence range”, “low eCmax”, or “very low eCmax”, based on
published levels [13, 15]. Low eCmax-levels were defined
as follows: isoniazid 2–3 mg/l, rifampicin 4–8 mg/l, rifab-
utin 0.2–0.3 mg/l and ethambutol 1–2 mg/l. Very low eCmax
levels were defined as isoniazid <2 mg/l, rifampicin <4 mg/
l, rifabutin <0.2 mg/l and ethambutol <0.1 mg/l. As a res-
ult of a lack of pyrazinamide differentiation for low and
very low levels, only “low eCmax” was defined as below the
lower limit of the reference range of <20 mg/L. In cases
of multiple eCmax values in a patient with several sampling
periods, the attribution to one of the groups was based on
two-thirds of the values being within the above predefined
ranges. Treatment outcome was defined according to WHO
guidelines (cured, treatment completed, treatment failure,
death) based on clinical presentation, imaging and microbi-
ological findings [2].
Results
Patient characteristics
A total of 17 patients were included. Baseline characterist-
ics are summarised in table 1. Three patients presented with
pulmonary TB, and 14 patients with disseminated or extra-
pulmonary TB. TB was proven in 14 patients, and highly
suspected in three patients (table 2).
Treatment
The TB treatment regimen consisted of first-line single-
component antituberculosis drugs or fixed-dose combina-
tions. In Switzerland, licensed antituberculosis drugs in-
clude four fixed-dose combinations (consisting of two to
four drugs) and seven single component antituberculosis
drugs. The initial dosages for all antituberculosis drugs
were prescribed as recommended in the product inform-
ation; in cases using single component antituberculosis
drugs the approximate weight-adapted dosage was chosen
(table 3).
Eight patients had directly observed therapy, four patients
took their drugs without supervision and no information
regarding drug observed therapy was available for the re-
maining patients. Three of all patients took antituberculosis
drugs with or after meals to prevent nausea and eight pa-
tients took their antituberculosis drugs while fasting. In six
patients timing in regard to meals was not documented.
Most patients (15/17) received comedication during the
study period. These were mainly HIV protease inhibitors
(5/17 patients) and Pneumocystis jirovecii / Toxoplasma
gondii prophylaxis. Patients on antiretroviral therapy with
a protease inhibitor received 150 mg rifabutin three times
a week instead of daily rifampicin. Nine patients were
intermittently treated with steroids owing to cerebral or
myelin involvement, or immune reconstitution inflammat-
ory syndrome. In 10 of 17 cases second-line TB drugs,
including fluoroquinolones, macrolides and aminoglycos-
ides, were coadministered. Seven of the 17 patients were
treated according the TB guidelines with initially four fol-
lowed by two antituberculosis drugs [3]. Three patients re-
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Table 1: Baseline characteristics of the 17 enrolled patients with proven or highly suspected tuberculosis.
Characteristics, n (% or range) n
Median age (yrs) at time of TB diagnosis 39 (21–71)
Male gender 10 (59)
Switzerland 4
Other European countries 3
Sub-Saharan Africa 6
Asia 1
Region of origin
Central/ South America 3
History of previous TB treatment 12 (71)
Median BMIa, at the time of TB diagnosis 22.4 (13.0–32.7)
Tobacco smoker 5 (29)
Nondrinkers / moderate drinkers 12 (71)
Heavy drinkers 2 (12)
Previous harmful alcohol use 1 (6)
Self-reported alcohol consumptionb
Unknown 2 (12)
HIV-infected individuals 7 (41)
HIV-infected individuals on ART 6 (36)
Diabetes 2 (12)
Comorbidities
Othersc 13 (76)
Proven TB 14 (82)Diagnosis
Highly suspected TB 3 (18)
ART = antiretroviral therapy; HIV = human immunodeficiency virus; TB = tuberculosis
The percentages were rounded and may not sum 100%.
a Body mass index (weight [kg] / square of height [m2]),
b moderate drinkers defined as women not more than one drink a day, men not more than two drinks a day; heavy drinkers defined as more than
seven drinks per week or three per occasion or more than 14 drinks per week or four per occasion
c stem cell transplantation and chemotherapy due to multiple myeloma, cerebral toxoplasmosis, renal failure, Pneumocystis jiroveci-pneumonia,
pulmonary aspergillosis, chronic hepatitis C
Table 2: Individual eCmaxa of isoniazid (INH), rifampicin (RMP), rifabutin (RFB), pyrazinamide (PZA), and ethambutol (EMB) and outcome of tuberculosis (TB).
Patient TB
diagnosis
Comorbidity TB
manifestation
INH eCmax RMP eCmax RFB eCmax PZA eCmax EMB eCmax Days of
treatment
Outcome
1 Proven No Disseminated ↓↓ ↓ NA ↓ = 450 Cured
2 Proven HIV Bone ↓ NA * NA ↓ 899 Cured
3 Proven HIVb Disseminated * NA * = NA 168 Cured
4 Proven HIVc Disseminated = = NA ↑ ↓ 23 Died from TB
5 Proven No Lymph node NA ↓ NA = NA 182 Cured
6 Proven HIV Pulmonary ↓↓ ↓↓ NA = NA 350 Cured
7 Proven SCTd Disseminated ↓↓ ↓↓ NA ↓ NA 145 Cured
8 Proven No Bone ↓↓ ↓↓ NA NA NA 372 Cured
9 Proven HIV Disseminated ↓↓ NA ↓↓ = * 270 Cured
10 Proven No Abscess NA ↓↓ NA NA NA 363 Cured
11 Proven HIV Disseminated ↓↓ NA * ↑ = 183 Cured
12 Proven Pancreas
Cae
Pulmonary ↓↓ ↓↓ NA = = 206 Cured
13 Proven HIVf Pulmonary ↓↓ NA * = NA 189 Cured
14 Proven No Bone ↓↓ ↓ NA ↑ NA 719 Cured
15 Highly
suspected
No Bone ↓↓ ↓ NA = NA 369 Cured
16 Highly
suspected
No Lymph node ↓ = NA NA NA 263 Cured
17 Highly
suspected
No Disseminated NA NA NA NA = 237 Cured
a estimated Cmax is the defined highest measured concentration independent of sampling collection time
Other comorbidities:
b Pneumocystis jiroveci pneumonia.
c suspected tuberculous meningitis.
d pulmonary aspergillosis and cerebral toxoplasmosis.
e pancreas carcinoma.
f stem cell transplantation (SCT) due to multiple myeloma.
More than or equal to 66% of the measurements were: = within reference range, ↓ low concentrations (INH 2–3 mg/l, RMP 4–8 mg/l, RFB 0.2–0.3 mg/l, PZA 10–20 mg/l,
EMB 1–2 mg/l), ↓↓ very low concentrations (INH <2 mg/l, RMB <4 mg/l, RFB <0.2 mg/l, PZA <10 mg/l, EMB <1 mg/l), * no significant trend to a defined range, NA not
available i.e. drug was not part of the treatment regimen or measurement not done
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ceived in addition to the usual TB-therapy fluoroquino-
lones, macrolides and aminoglycosides between 2 to 90
days until drug sensitivity results were available. In two pa-
tients a first-line antituberculosis drug was substituted by
a fluoroquinolone because of toxicities. In the remaining
five patients second-line antituberculosis drugs were added
either because of delayed treatment response or lack of
drug sensitivity tests. Only in two cases fluoroquinolones
were administered for the whole treatment period.
Figure 1
Panels A-E represent the highest measured concentration
(estimated Cmax) from each sampling period for each
antituberculosis drug with its corresponding dosages.
Panels a-e represent sampling periods with multiple consecutive
measurements.
For all panels: Grey area shows published reference ranges [13].
White symbols represent antituberculosis drug levels determined
during multiple sampling periods, black symbols represent levels
determined in periods with only one sample taken.
Course of treatment and treatment duration
Sixteen of 17 (94%) patients completed therapy and were
cured, based on WHO guidelines definition. Median treat-
ment duration among all 17 patients was 317 days (range
23–899 days, table 2). TB treatment of more than 12
months was observed in patients with bone involvement,
spondylitis or disseminated TB. The median time for spu-
tum conversion by microscopy and culture in patients with
pulmonary TB was 17 days, which was documented in all
but one patient. In one patient with a lack of sputum con-
version and progressive radiological findings after the first
2 months of recommended TB treatment (isoniazid 300
mg, rifampicin 600 mg, pyrazinamide 1 500 mg and eth-
ambutol 1 200 mg), this regimen was extended for another
3 months and expanded to the combination of five drugs,
including moxifloxacin. In this case of delayed treatment
response, a single blood sample at 6 h after drug inges-
tion was collected for isoniazid, rifampicin and pyrazin-
amide. The measurement showed isoniazid and rifampi-
cin concentrations below and only the pyrazinamide value
within the reference range. Even though isoniazid and ri-
fampicin doses were not increased, sputum conversion was
confirmed after 5 months of TB treatment.
Therapeutic drug monitoring
We examined the concentrations of five antituberculosis
drugs in 175 serum samples of 17 patients. In 12 (71%) pa-
tients, blood samples for therapeutic drug monitoring were
collected repeatedly during TB treatment. In 14 (82%) pa-
tients, the first sampling was performed 6 days to 2 months
after treatment start; in three patients the first therapeutic
drug monitoring was performed after 6 months.
Physicians ordered therapeutic drug monitoring in the fol-
lowing situations: no or delayed clinical improvement des-
pite accurate antituberculosis drug administration in four
(24%) patients, clinical worsening in three (18%) patients,
absence of urinary isoniazid detection in two (12%) pa-
tients, and suspected antituberculosis drug toxicity in five
(29%) patients (elevated liver function parameters, poly-
neuropathy). Therapeutic drug monitoring was performed
after antituberculosis drug dose adjustment in 7 (41%) pa-
tients. In four patients the dose was adjusted without
follow-up measurements. The most frequently reported
reasons for dose adjustments were low eCmax levels,weight
increase during the treatment period, change to fixed-dose
combinations, and drug-drug interactions.
One fourth of the measurements were not collected at the
suggested sampling times. They were performed at any
time between 0 h (trough level) and 12 h after dosing.
However, most measurements were collected at 2 h (35%)
and 4 h (23.5%). Fifty-seven (33%) of 175 determinations
were measured at one time only and defined as eCmax. Of
these, 49% were collected 2 h after drug intake.
In all but one patient (94%), at least one eCmax value was
below the reference range. Furthermore, five of 17 patients
(29%) had single measurements with antituberculosis drug
concentrations below the detectable range. Estimated Cmax
was below the reference range in 78% of isoniazid, 90% of
rifampicin and 50% of rifabutin measurements (table 3 and
fig. 1A–C). In contrast, 30% of pyrazinamide and etham-
butol eCmax values were below the reference range. Estim-
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ated Cmax was mainly at 2 h with all antituberculosis drugs
except pyrazinamide, for which 30% of eCmax values were
at 2 h and 4 h after drug intake, respectively (table 3).
Eight of 12 patients with follow-up measurements re-
peatedly showed low levels of at least one drug. Dose
was augmented in seven of these 12 patients. Isoniazid
dose was increased up to 450 mg daily in four patients. In
follow-up measurements of isoniazid eCmax, three patients
showed levels within the reference range. Dose-adaption
of ethambutol in one patient resulted in serum concentra-
tions within the range. No increase of the serum concentra-
tions of pyrazinamide was documented after dose adjust-
ment. No significant correlation between dosage and eCmax
was found for any antituberculosis drug (R2 <0.09).
Safety
In one case of disseminated TB treatment was stopped after
6 months owing to possible drug-induced liver injury and
persistent liver enzyme elevation, despite treatment cessa-
tion. In three other cases therapy was temporarily inter-
rupted as a result of transitionally elevated liver enzymes,
transient polyneuropathy, or neuropathy of the optic nerve.
After restarting treatment with antituberculosis drugs no
further symptoms were documented.
Outcome
All patients were cured except one who died from dissem-
inated TB, suspected TB meningitis and untreated HIV in-
fection (3 CD4 cells/mcl and HIV-1-RNA 1 Mio copies/
mL) within 23 days after starting TB treatment, after he had
presented very late. There were no reports of relapse or re-
infection among the other patients after completion of ther-
apy up to the conclusion of the study period in March 2014.
One patient was lost to follow-up because he had left the
country.
Discussion
In this retrospective analysis of 17 patients, all but one pa-
tient were cured from TB even though 64% of all eCmax
values of first-line TB drugs were found to be below the
widely used reference ranges [13]. Isoniazid and rifampicin
eCmax were below the reference ranges in a high percentage
of cases (>80%), whereas pyrazinamide and ethambutol
eCmax were within the reference range in most of the
samples (>70%).
Our results are in line with those of several other studies
reporting a high prevalence of low antituberculosis drug
serum concentrations in TB patients with or without HIV
coinfection and daily drug administration [10, 16, 17,
20–23]. All investigators measured drug concentrations 2
hours after drug intake, and some at 6 hours. A high per-
centage of low serum concentrations were found for iso-
niazid and rifampicin especially. However, most studies
were purely descriptive, and the correlation with the treat-
ment outcome was not investigated, or was inconclusive.
So far, only two prospective studies have systematically
investigated the association of low antituberculosis drug
levels and treatment outcome. Chideya et al. investigated
225 patients for treatment outcome and antituberculosis
drug pharmacokinetics (i.e., area under the concentration-
time curve [AUC] 0-6h and peak concentrations [Cmax])
in Botswana [15]. Although 85% of all rifampicin levels
(Cmax) and 37% of the isoniazid levels were below the ref-
erence ranges, only a pyrazinamide Cmax below the refer-
ence range was associated with treatment failure. In a pro-
spective study by Burhan et al. C2h levels were determined
in 181 patients and correlated with treatment outcome at
week 4 and 8 [23]. Similarly low C2h levels were observed
in a high proportion of patients, but only low pyrazinamide
levels were associated with poor treatment outcome.
The similar prevalence of low antituberculosis drug levels
in these studies and the lack of correlation with the out-
come, or TB recurrence, suggest that the reference ranges
defined for isoniazid and rifampicin might not represent the
plasma concentrations reached with usual doses in TB pa-
tients but rather represent pharmacokinetic data of healthy
volunteers from which they were derived. Furthermore, at
least some of these ranges probably do not represent the
therapeutic range in combined TB treatment. This would
explain the favourable outcome in our patients who had
Table 3: Comparison and categorisation of estimated Cmax with published reference ranges for first-line antituberculosis drugs (ATD).
Daily dose (mg/kg of
body weight range)
Reference range of
absolute Cmax
a (usual
dose)b
Median eCmax
a mg/l,
(range)
eCmax
a categories Time point at which eCmax
a was
determined %e
Within
reference
rangeb
Lowc Very lowd C2h C4h C6h
INH 200–450 mg
(3.13–9.38)
3–6 mg/l (300 mg/d) 1.2 (<0.1–5.4) 21.6% 21.6% 57% 60.5% 15.8% 2.6%
RMP 480–720 mg
(7.5–10.67)
8–24 mg/l (600 mg/d) 3.8 (<0.02–10.82) 10% 35% 55% 50% 15% 10%
RFB 600 mg (2.03–11.67) 0.3–0.9 mg/l (300 mg/d) 0.274 (0.047–0.483) 50% 30% 20% 40% 10% 30%
PZA 1000–1500 mg
(18.75–39.84)
20–50 mg/l (25 mg/kg/
d)
30.7 (<5.0–77.2) 70% 30% – 30.4% 30.4% 8.7%
EMB 800–2400 mg (18–25) 2–6 mg/l (25 mg/kg/d) 2.6 (1.0–6.2) 70% 30% 0% 50% 20% 10%
EMB = ethambutol INH = isoniazid; PZA = pyrazinamide; RFB = rifabutin; RMP = rifampicin
a Estimated Cmax defined as highest measured serum concentration independent of sampling time.
b Reference ranges (Peloquin, C.A, Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–83 [13].
c Defined as INH 2–3 mg/l, RMP 4–8 mg/l, RFB 0.2–0.3 mg/l, PZA <20 mg/l, EMB 1–2 mg/l.
d Defined as INH <2 mg/l, RMP <4 mg/l, RFB <0.2 mg/l, EMB <1 mg/l.
e Single and multiple sampling.
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a high rate of low and very low isoniazid and rifampicin
levels.
In-vitro data show a clear concentration-dependent effect
on Mycobacterium tuberculosis for all first-line antituber-
culosis drugs [24]. Rifampicin and isoniazid have the
highest bactericidal activity in vitro, those of ethambutol
and pyrazinamide are considerably lower [25]. In suscept-
ible Mycobacterium tuberculosis, rifampicin and isoniazid
minimal inhibitory concentrations are much lower than the
usual antituberculosis drug serum concentration achieved,
while the minimal inhibitory concentration values for eth-
ambutol and pyrazinamide are closer to the drug levels
[26]. These observations might explain the association of
low pyrazinamide levels with treatment failure and the
favourable outcome despite low isoniazid and rifampicin
levels.
Indeed, only studies that correlated outcome with a once
weekly or twice weekly regimen of isoniazid and rifampi-
cin found a significant association between low plasma
concentrations and poor outcome [27–29]. This indicates
that effective plasma concentrations are not reached by low
dosing regimens. On the other hand, higher than stand-
ard rifampicin doses were correlated with a faster sputum
conversion, which implies the possibility of a shorter TB
treatment duration due to the concentration-dependent anti-
mycobacterial effect [30]. Mehta et al. showed low concen-
trations of rifampicin in a subgroup of patients with doc-
umented slow response to the standard treatment regimen
[29]. Dose adjustments for rifampicin from the convention-
ally used 600 mg up to 900 mg resulted in Cmax within
reference ranges with good treatment outcomes in all pa-
tients. This result emphasises the dose-dependent effect of
rifampicin.
The 2 h postdose concentration was reported to be the
most informative pharmacokinetic sampling time if con-
secutive measurements are not possible to determine true
peak concentrations [13]. Because of a delay of drug ab-
sorption in some patients, a second sampling is recommen-
ded 4–6 h after drug intake. In our patients, about one-third
of samples were taken at 2 h. Several patients had only
one measurement, and some had multiple samples taken,
mostly 2–4 and 4–6 h postingestion, enabling a more exact
estimation of peak antituberculosis drug concentration (fig.
1a–e).
We found that the time to reach peak concentrations was
variable in the multiple samples and patients. When C2h
value was low in patients after single determinations, it
was difficult to differentiate between real low concentra-
tions and missed peak concentrations. Peak concentrations
for rifabutin were most often reached after 6 h (fig. 1c),
which was later than expected from other pharmacokinetic
studies, where the peak level was usually reached at 3–4 h
[31]. This delay of absorption in our patients may be due
to drug intake with food. In two of our patients target range
would have been missed in the case of a single determ-
ination at 2 h. This underlines the importance of an addi-
tional determination at 4 h for rifabutin and pyrazinamide,
if the drug is taken fasting as recommended. Delayed ab-
sorption was rarely seen with the remaining antitubercu-
losis drugs. In patients with multiple sampling of rifampi-
cin and isoniazid, C2h represented the peak concentration
in most cases. According to literature, rifampicin peak ser-
um concentration is typically reached 2 h postdose; there-
fore, C2h values for rifampicin below the reference range
reflect an effective low Cmax [18, 32, 33]. However, iso-
niazid peak concentrations were frequently already reached
after 0.5-1.5 h [34–36], and C2h values underestimate true
peak concentrations, especially in fast acetylators with a
short isoniazid half-life of less than 2 h [36]. In our study,
eCmax of isoniazid was measured after 2 h in most cases
(60%) (table 2 and fig. 1a), and the majority of these values
were below the reference range. The 2 h sample time could
explain the high proportion of very low isoniazid C2h val-
ues in our patients, as well as in the cited therapeutic drug
monitoring studies. A significantly lower rate of isoniazid
concentrations (37%) below the reference range were re-
ported in the study of Chideya et al. [15], where the maxim-
um serum concentration was determined by measurements
at 1 h, in addition to 2 and 6 h. This implies that addition-
al sampling of isoniazid after 1 h increases the probability
of measuring true Cmax. Based on these findings we now
recommend sampling after 1 h, 2 h and 4 h. If rifabutin is
taken with food sampling after 6 h instead of 4 h is advis-
able.
Our retrospective analysis has several limitations. The
sample size was small and the study was conducted among
a heterogeneous group of patients with different sites of in-
fection and treatment regimens. Duration of treatment was
significantly longer for patients with TB involvement of
the bone or disseminated TB. Blood sampling was done in
the absence of a firm standard protocol. Finally, for patients
who underwent therapeutic drug monitoring with subse-
quent dose adjustments, repeated serum measurements
were not always performed. Favourable outcome might
have been influenced by several factors such as prolonga-
tion of treatment, dose increase during treatment and addi-
tion of second line antituberulosis drug. Nevertheless, the
strength of this study is the well described real life setting
correlating the antituberculosis drug concentrations with a
long-term clinical follow-up.
In summary, our study indicates a need to validate whether
the reference ranges published by Peloquin, and widely
used ever since, represent reliable therapeutic target con-
centrations that correlate with the TB treatment outcome
in the clinical setting. Our data suggest that the therapeutic
ranges for isoniazid and rifampicin might be below the sug-
gested ranges of Peloquin et al., especially when combin-
ation treatment is used. A large prospective clinical trial
in TB patients is needed to properly address the question
of the optimal timing of drug level measurements for first-
line antituberculosis drug in order to identify the true peak
concentration and in order to correlate peak concentrations
with TB treatment outcome. This will lay ground to re-
liably treat difficult TB cases guided by therapeutic drug
monitoring.
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Figure 1
Panels A-E represent the highest measured concentration (estimated Cmax) from each sampling period for each antituberculosis drug with its
corresponding dosages.
Panels a-e represent sampling periods with multiple consecutive measurements.
For all panels: Grey area shows published reference ranges [13]. White symbols represent antituberculosis drug levels determined during
multiple sampling periods, black symbols represent levels determined in periods with only one sample taken.
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